|
|
International Faculty
|
 |
|
Invited Faculty
|
|
Renu Virmani, MD |
CVPath Institute, Inc.
USA
|
|
|
|
| Program |
|
| Date |
Time |
Place |
Session / Title |
Role |
|
| April 28 |
12:45 PM - 1:45 PM |
Room 203, Level 2 |
A Discussion of Lutonix Drug Coated Balloon Technology |
Moderator |
| April 28 |
12:45 PM - 1:05 PM |
Room 203, Level 2 |
A Discussion of Lutonix Drug Coated Balloon Technology
Not All DCBs Are Created Equal: Side by Side Pre-clinical Safety Evaluation of Leading DCBs |
Lecturer |
| April 28 |
5:33 PM - 6:45 PM |
Room 105, Level 1 |
HKSTENT @ TCTAP 2015 |
Panelist |
| April 29 |
8:40 AM - 9:10 AM |
Interview Lounge, Level 2 |
BVS (Bioresorbable Vascular Scaffold) for Coronary Artery Disease |
Interviewee |
| April 29 |
11:30 AM - 12:30 PM |
Endovascular & Structural Heart Theater, Level 1 |
I. Featured Lectures |
Panelist |
| April 29 |
11:30 AM - 11:40 AM |
Endovascular & Structural Heart Theater, Level 1 |
I. Featured Lectures
Unique Demands of the Femoral Anatomy and Pathology and the Need for Unique Interventions |
Lecturer |
| April 29 |
2:00 PM - 3:17 PM |
Room 104, Level 1 |
Imaging & Physiology Summit |
Panelist |
| April 29 |
2:00 PM - 2:08 PM |
Room 104, Level 1 |
Imaging & Physiology Summit
Natural History of Vulnerable Plaque: Targets for Risk Stratification |
Lecturer |
| April 29 |
4:36 PM - 4:48 PM |
Coronary Theater, Level 1 |
Coronary Session II
Autopsy Studies of TAVR - What Have We Learnt? |
Lecturer |
| April 29 |
5:46 PM - 5:53 PM |
Room 104, Level 1 |
DES & BVS
No, It is Not Yet Ready. |
Lecturer |
| April 30 |
7:00 AM - 8:10 AM |
Room 105, Level 1 |
DES Failure |
Moderator |
| April 30 |
7:00 AM - 7:08 AM |
Room 105, Level 1 |
DES Failure
DES Failure: Pathologic Findings and Treatment |
Lecturer |
|
|
|
|
|
|
|
|
|
|
|
 |
CardioVascular Research Foundation(CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
Tel: 82-2-3010-7255/ Business registration number: 215-82-06387
Copyright ⓒ 2002 CVRF, Seoul, Korea. All rights reserved. |
  |
  |
|
